Inhibrx Biosciences, Inc. $INBX Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC decreased its stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 55.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,488 shares of the company’s stock after selling 90,421 shares during the period. Kennedy Capital Management LLC owned 0.49% of Inhibrx Biosciences worth $5,648,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of INBX. Morgan Stanley boosted its stake in Inhibrx Biosciences by 163.7% during the 4th quarter. Morgan Stanley now owns 1,167,728 shares of the company’s stock worth $92,251,000 after purchasing an additional 724,872 shares during the period. Capital Research Global Investors acquired a new stake in Inhibrx Biosciences during the 4th quarter worth $33,304,000. Caligan Partners LP acquired a new stake in Inhibrx Biosciences during the 3rd quarter worth $7,961,000. State Street Corp boosted its stake in Inhibrx Biosciences by 83.9% during the 4th quarter. State Street Corp now owns 374,961 shares of the company’s stock worth $29,622,000 after purchasing an additional 171,038 shares during the period. Finally, Readystate Asset Management LP boosted its stake in Inhibrx Biosciences by 534.1% during the 3rd quarter. Readystate Asset Management LP now owns 170,158 shares of the company’s stock worth $5,731,000 after purchasing an additional 143,324 shares during the period. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Biosciences Stock Up 1.4%

INBX stock opened at $93.51 on Tuesday. Inhibrx Biosciences, Inc. has a one year low of $13.97 and a one year high of $155.29. The stock has a market capitalization of $1.37 billion, a PE ratio of -11.15 and a beta of 3.33. The company has a debt-to-equity ratio of 12.58, a quick ratio of 6.46 and a current ratio of 6.46. The company has a fifty day moving average of $100.95 and a 200-day moving average of $85.11.

Inhibrx Biosciences (NASDAQ:INBX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($2.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.47). As a group, analysts expect that Inhibrx Biosciences, Inc. will post -10.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Lifesci Capital upgraded shares of Inhibrx Biosciences to a “strong-buy” rating in a research note on Friday, April 24th. Zacks Research upgraded shares of Inhibrx Biosciences to a “hold” rating in a research note on Thursday, April 9th. Stifel Nicolaus initiated coverage on shares of Inhibrx Biosciences in a research note on Wednesday, April 8th. They issued a “buy” rating and a $150.00 target price for the company. Finally, Wall Street Zen upgraded shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $150.00.

Inhibrx Biosciences Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.